tbuckley/cabot-search huggingface dataset:
Single-cell transcriptomics and chromatin accessibility profiling elucidate the kidney-protective mechanism of mineralocorticoid receptor antagonists
Authors: Amin Abedini, Andrea Sánchez-Navaro, Junnan Wu, Konstantin A. Klötzer, Ziyuan Ma, Bibek Poudel, Tomohito Doke, Michael S. Balzer, Julia Frederick, Hana Cernecka, Hongbo Liu, Xiujie Liang, Steven Vitale, Peter Kolkhof, Katalin Susztak
Journal: Journal of Clinical Investigation (2023)

Mineralocorticoid excess commonly leads to hypertension and kidney disease. In our study, we employed single-cell expression and chromatin accessibility tools to characterize the mineralocorticoid target genes and cell types. We demonstrated that mineralocorticoid effects are established through open chromatin and target gene expression, primarily in principal and connecting tubule cells, and to a lesser extent, in segments of the distal convoluted tubule cells. We examined the kidney-protective effects of steroidal and non-steroidal mineralocorticoid antagonists (MRAs), as well as amiloride, an epithelial sodium channel inhibitor, in a rat model of deoxycorticosterone acetate, unilateral nephrectomy, and high salt consumption-induced hypertension and cardiorenal damage. All antihypertensive therapies protected from cardiorenal damage. However, finerenone was particularly effective in reducing albuminuria and improving gene expression changes in podocytes and proximal tubule cells, even with equivalent blood pressure reduction.
Monitoring and reporting of adverse effects of testosterone prescribing for gender affirmation at general practice clinics - Data from the PUSH! Audit
Authors: Beng Eu, Joshua Dawe, Matthew Dunn, Julian Grace, Kevin Lee, Scott Griffiths, Mark Bloch, David Baker, Clara Soo, Fiona Bisshop, Mark Stoové
Journal: International Journal of Transgender Health (2023)

Prescribing testosterone for gender affirming hormone therapy (GAHT) has been increasing in Australia with much of this practice done by general practitioners (GPs) and there are current AusPATH guidelines on how this can be done appropriately. There has been limited data collected from GPs about how well these patients are monitored and the adverse effects (AEs) that are experienced by this population of patients.
EP08.03-04 MicroDurva: A Prospective Study to Investigate the Role of Microbiome in Predicting the AEs from Durvalumab in Post-CCRT NSCLC Patients
Authors: J. Zhang, C.H. Huang, H. Khan, Q. Dai, D. Satelli, G.N. Gan, M. Phadnis, C. Zhong
Journal: Journal of Thoracic Oncology (2023)
EP12.03-04 Prognostic Value of TP53 Commutations Among Hispanic Patients with Advanced EGFR-positive NSCLC Treated with First Line Osimertinib
Authors: L. Rojas, J. Zuluaga, A. Ruiz-Patiño, J. Rodríguez, O. Arrieta, D. Chamorro, L. Corrales, C. Martin, L. Viola, L. Raez, C. Vargas, J. Otero, H. Carranza, R. Motta, G. Cruz, A. Valencia, C. Rolfo, R. Rossell, A. Cardona
Journal: Journal of Thoracic Oncology (2023)
EP13.01-11 Study of NLI Use in the First Line of Atezolizumab Plus Chemotherapy
Authors: P. Cruz, B. Riesco Montes, L. Fernandez Franco, S. Falagan, L.E. Chara, L. Gutierrez-Sainz, S. Simon Alonso, S. Cerezo, O. Higuera, J. Villamayor, R. Galan Moral, J.C. Villa, R. Alvarez Cabellos, R. Lopez Bajo, J. Portela, M. Serrano, A.K. Santos Rodriguez, J.R. Muñoz-Rodriguez
Journal: Journal of Thoracic Oncology (2023)
EP09.03-02 Local Ablation Induces Abscopal Effects and Improves the Efficacy of Continuous ICIs in Advanced NSCLC Patients with Oligo-progression
Authors: L. Wu, C. Shao, B. Chen, J. Yu, X. Zhi, F. Zhou, C. Zhou, Y. Xu, S. Ren
Journal: Journal of Thoracic Oncology (2023)
EP06.06-05 Circular RNA hsa_circ_0067705 Expression as a Potential Diagnostic Biomarker for Malignant Pleural Effusion
Authors: R.S.Z. Taleb, A.I. Baess, E.S. Elsawy, A.A. Kandil, O.A. Sharaki
Journal: Journal of Thoracic Oncology (2023)
EP17.01-02 Data Mining to Build Metrics. A Feasible Assessment of Quality of Care for Stage III Non-small Cell Lung Cancer (NSCLC)
Authors: J.C. Sánchez González, B. Nuñez Garcia, M. Blanco Clemente, V. Calvo de Juan, Y. Garitaonaindia Diaz, M. Martinez Cutillas, A. Collazo Lorduy, M. Mendez Garcia, B. Cantos Sanchez de Ibargüen, A. Gonzalez Sanchez, M.I. Melero Cipres, I. Redondo Canovas del Castillo, M. Uribarren Movilla, M.M. Sanchez del Corral, M. Provencio Pulla
Journal: Journal of Thoracic Oncology (2023)
EP11.03-30 What Are Favorable Clinicopathological Factors and Types of Therapy for Postoperatively Recurrent NSCLC Patients?
Authors: Y. Matsumura, A. Enta, Y. Maruya, S. Inomata, H. Yamaguchi, H. Mine, M. Watanabe, Y. Ozaki, S. Muto, N. Okabe, K. Hamada, H. Suzuki
Journal: Journal of Thoracic Oncology (2023)
EP07.05-11 Efficacy and Safety of Osimertinib Therapy in High-Risk Stage I EGFRm NSCLC after R0 Resection(OSTAR): A Prospective, Single-Arm Study
Authors: D. Yue, C. Chen, R. Jiang, Z. Zhang, S. Wang, B. Zhang, L. Sun, X. Wang, J. Xie
Journal: Journal of Thoracic Oncology (2023)

of 57 patients with ES-NSCLC and ILD who underwent definitive SBRT between January 2009 and December 2019.The most common SBRT dose was 60 Gy in 4 fractions and the median biologically effective dose with a/b of 10 was 134.4 Gy (range, 75-150 Gy).The outcomes of survival, toxicities and the relationships between outcomes and clinical factors were investigated.Results: The median age of all patients was 73 (range, 61-88), and the median follow-up period was 21.6 (range, 1.6-93.5)months.The average values for forced expiratory volume in one second (FEV1) and diffusing capacity of the lung for carbon monoxide were 76.0 and 47.5, respectively.During the follow up period, 11 patients developed grade 3 or higher radiation induced pneumonitis, and 34 patients had died.The most frequent cause of death was lung cancer in 20 patients, followed by other lung disease in 14 patients, such as pneumonitis, exacerbation of ILD and pneumonia.The rates of 2-year freedom from local recurrence (FFLP), progressionfree survival (PFS) and overall survival (OS) were 70.3%, 32.5% and 50.9%, respectively.Conclusions: Patients with ES-NSCLC and ILD had a poor prognosis and high incidence of treatment related lung toxicity after SBRT.Nevertheless, considering that lung cancer progression is the most common cause of death in these patients, cancer-directed treatment should be considered despite its toxicities.
EP08.02-16 Higher Radiation Dose to Immune Cells is a Negative Prognostic Factor in Locally Advanced Non-Small Cell Lung Cancer (LA-NSCLC)
Authors: C. Friedes, N. Yegya-Raman, M. Iocolano, S.H. Lee, W. Su, L. Duan, B. Li, A. Doucette, R. Cohen, C. Aggarwal, W. Levin, K. Cengel, K. Teo, C. Langer, Y. Xiao, J. Bradley, S. Feigenberg
Journal: Journal of Thoracic Oncology (2023)
EP08.02-03 Real World Experience of Survival Outcomes in Consolidative Durvalumab in Unresectable Stage III Non-Small Cell Lung Cancer (NSCLC)
Authors: N. Pringle, J.A. Fletcher, C. Morton, W.J. Mullally, M. Arneil, K. O'Byrne, W. Xu
Journal: Journal of Thoracic Oncology (2023)
EP07.01-16 The Relationship of FDG PET-SUVm and Glucose Metabolism and Contribution to Early-Stage Non-Small Cell Lung Cancer Survival
Authors: K. Kernstine, B.M. Faubert, Q.N. Do, T.J. Rogers, C.T. Hensley, L. Cai, J.R. Torrealba, D.H. Oliver, A. Kandathil, R.E. Lenkinski, C.R. Malloy, J.K. Waters, S.I. Reznik, M.E. Jessen, R.J. Deberardinis
Journal: Journal of Thoracic Oncology (2023)
EP06.05-09 Computational Pathology-Based Assessment of cMET IHC Expression for Patient Selection in the Treatment of MET Overexpressing NSCLC
Authors: S. Christ, A. Kapil, I. Bisha, J. Chan, A. Andoni, C. Cotoi, M. Schick, G. Schmidt, R. Hartmaier, H. Sade
Journal: Journal of Thoracic Oncology (2023)
EP11.01-08 GSDME-dependent Pyroptosis Affects the Prognosis and Response to Immunotherapy in Lung Adenocarcinoma
Authors: P. Cao, G. Zhu, Y. Li, H. Huang, D. Wu, H. Zhang, M. Liu, C. Chen, H. Liu, J. Chen
Journal: Journal of Thoracic Oncology (2023)
P2.01-01 Initial Result of the ImmunoPET Phase1 Study: Characterising PD-L1 During Chemoradiotherapy with 89Zr- Durvalumab (MEDI4736) PET/CT
Authors: F. Hegi-Johnson, S. Rudd, P. Roselt, C. Wichmann, S. Sursock, T. Akhurst, P. Jackson, R. Hicks, A. Scott, P. Donnelly, T. John, M. MacManus
Journal: Journal of Thoracic Oncology (2023)
EP11.03-02 Characterizing Neurologic Immune-related Adverse Events Using Consensus Disease Definitions
Authors: A. Pabani, M. Eskian, L. Burton, J. Hillis, M. O'Hare, G.S. Manzano, S. Shalhout, L. Zubiri, D. Miller, K.L. Reynolds, A.C. Guidon
Journal: Journal of Thoracic Oncology (2023)
EP07.04-22 Current Biomarker Testing Practices for Early Stage Non-small Cell Lung Cancer (NSCLC) In Community and Academic Centers in the US
Authors: M. Smeltzer, M. Vimolratana, M. Shiller, S.M. Cattaneo, J. Gray, B. Stiles, J. Aversano, A. Lile, E. Plotkin, J. Kim, L. Boehmer
Journal: Journal of Thoracic Oncology (2023)
P2.06-12 The Safety and Efficacy of Durvalumab as 1st Line Therapy in Patients with Advanced NSCLC and ECOG PS of 2
Authors: K. Shaverdashvili, V. Reyes, H. Wang, D. Mehta, C. Marsh, J.K. Waas, R.A. VanderWeele, S.M. Peracha, H. Liang, D.E. Gerber, J. Dowell, L.C. Villaruz
Journal: Journal of Thoracic Oncology (2023)
P2.09-14 Clinical Characteristics and Outcomes of Patients with EGFR-mutant Lung Cancer with Acquired BRAF Alterations
Authors: J. Sui, S.R. Yang, A.S. Bowman, P. Vankayala, C. Falcon, R. Somwar, A.E. Drilon, G.J. Riely, M.G. Kris, M. Ladanyi, H.A. Yu, M. Offin
Journal: Journal of Thoracic Oncology (2023)
EP11.03-21 Incidence of Cardiotoxicity in Patients Treated for Non-Small Cell Lung Cancer with Immune Checkpoint Inhibitors
Authors: I.N. Carpenter, K.B. Brice, D. Walker, K. Dumais, A.M. Alvarez, N.S. Cohen, L.E. Raez
Journal: Journal of Thoracic Oncology (2023)
P2.07-05 Immune Checkpoint Blockers in Lung Cancer after Solid Organ Transplantation: INNOVATED Registry
Authors: J. Remon Masip, E. Auclin, F. Aboubakar Nana, S. Schneider, O. Gautschi, L. Zubiri, T. Pierret, D. Rodriguez-Abreu, N. Blais, M. Aldea, F. Barlesi, D. Planchard, B. Besse
Journal: Journal of Thoracic Oncology (2023)
P2.26-02 Patient-Reported Symptom Monitoring Improves 1-Year Quality of Life in Lung Cancer Patients; the SYMPRO-Lung Trial
Authors: I. Walraven, N. Billingy, V. Tromp, N. Aaronson, J. Belderbos, H.J. Bogaard, J. Hugtenburg, B. Onwuteaka-Philipsen, L. van de Poll-Franse, C. van den Hurk, A. Becker-Commissaris
Journal: Journal of Thoracic Oncology (2023)
P2.17-01 Recent Patterns across Therapy Lines and Real-World Survival Post First Line PD-L1 Treatment for Small Cell Lung Cancer
Authors: H. Borghaei, J. Shaw, X. Pundole, A. Balasubramanian, E. Anderson, G. Bebb, T. Jiang, M. Pastel, P. Martinez, S. Ramalingam
Journal: Journal of Thoracic Oncology (2023)
P2.31-06 Real-World Treatment Patterns and Outcomes in Patients With Advanced NSCLC Treated After Prior Chemotherapy and Immunotherapy
Authors: D. Haggstrom, S.K. Mhatre, F. Chen, R. Gao, C. Carroll, R. Patel, J. Park, A. Descoteaux, M. Stokes, D. Daniel
Journal: Journal of Thoracic Oncology (2023)
P2.14-01 Patient-Reported Outcomes from IMfirst: Chemotherapy Plus Atezolizumab in a Real-World Setting of Extensive-Stage SCLC
Authors: M. Dómine Gómez, M. Cobo Dols, J. de Castro, A. Moreno Vega, S. Ponce Aix, E. Arriola, E. Carcereny, M. Majem Tarruella, G. Huidobro Vence, E. Esteban González, J. Fuentes Pradera, A.L. Ortega Granados, M. Guillot Morales, B. Massuti Sureda, L. Vilà, A. Blasco Cordellat, C.A. Fajardo, L. Crama, N. Lerones, R. García Campelo
Journal: Journal of Thoracic Oncology (2023)
EP03.04-02 Evaluation of Potential Therapeutic Targets with Experimental or FDA-approved Therapies in Thymic Tumor Microarrays
Authors: F. Ardeshir Larijani, T. Hou, R. Maniar, M. Kuhar, F. Perna, P. Loehrer, H. Mesa
Journal: Journal of Thoracic Oncology (2023)
EP07.04-11 Clinicopathological Features and Postoperative Prognosis of Bubble-like Appearance Type Lung Adenocarcinoma
Authors: K. Murakami, H. Saito, K. Watabe, N. Shigeta, N. Kikunishi, S. Shigefuku, T. Isaka, T. Nagashima, Y. Miyagi, T. Yokose, H. Ito
Journal: Journal of Thoracic Oncology (2023)
P2.10-07 ORA-LM: Molecular Analysis in Cerebrospinal Fluid of ALK or EGFR Positive NSCLC Patients with Leptomeningeal Metastases
Authors: T. van der Wel, M.C. Boelens, M. Jebbink, S.A. Smulders, M.A. Tiemessen, K.W. Maas, M.J. Luitse, A. Compter, R.P.B. Boltjes, N. Sol, K. Monkhorst, D. van den Broek, E.F. Smit, A.J. de Langen, D. Brandsma
Journal: Journal of Thoracic Oncology (2023)
EP03.03-09 Impact of Tyrosine Kinase Inhibitors on the Immune Response to SARS CoV2 Vaccination in Patients with Non Small Cell Lung Cancer
Authors: N.Y. Hernández Pedro, M. Arroyo-Hernández, V.A. Sosa-Hernandez, E. Romero-Nuñez, J.L. Maravillas-Montero, M. Orozco-Morales, P. Barrios-Bernal, J. Lucio-Lozada, D. Flores Estrada, O. Arrieta
Journal: Journal of Thoracic Oncology (2023)
EP03.03-01 IS1160 Transposon Mycobacterium Tuberculosis Detection in Lung Cancer - A Preliminary Study
Authors: H.K.P. Faisal, J. Zaini, D.R. Noor, M.I. Dhiya, E. Eylin, S.L. Andarini, E. Syahruddin, F. Yunus
Journal: Journal of Thoracic Oncology (2023)
P2.20-02 Thymomatous Myasthenia Gravis after Total Thymectomy at a Tertiary-Care Surgical Centre: a 20-Year Retrospective Review
Authors: A.L. McGuire, C. Huhyn, S. Sharma, A. Vieira, F. Jain, D. Lee, D. Mousa-Doust, K. Jack, M.M. Mezei, K. Chapman, H. Briemberg, J.J. Choi, K. Grant, J. Yee
Journal: Journal of Thoracic Oncology (2023)
P1.24-09 Spatially Defined Immune Response Signatures in 5μm Tumor Section of Resected T1-2N0M0 Lung Cancer Predict Clinical Outcome
Authors: P. Yang, R. Mudappathi, A. Maguire, J.(. Yi, C. Yanxi, I. Zaniletti, A. Kumar, J. Wampfler, P. Reck dos Santos, Y. Lou, J. D'Cunha, L. Liu, J. Diane, J. Wang, H. Tazelaar
Journal: Journal of Thoracic Oncology (2023)
P1.06-04 Phenotype Mapping of Patient-Derived Small Cell Lung Cancer Organoids Illuminate Subtype-Specific Therapeutic Vulnerability
Authors: T. Fukushima, H. Yasuda, H. Terai, J. Hamamoto, M. Okada, A. Saito, H. Takaoka, F. Ito, L. Shigematsu, S. Nukaga, K. Ohgino, S. Ikemura, I. Kawada, K. Soejima, K. Fukunaga, T. Sato
Journal: Journal of Thoracic Oncology (2023)
MA13.04 Final Overall Survival Analysis of Osimertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations (KCSG-LU15-09)
Authors: J.H. Cho, S.H. Lim, H.J. An, K.H. Kim, K.U. Park, E.J. Kang, Y.H. Choi, M.S. Ahn, J.-M. Sun, S.-H. Lee, J.S. Ahn, K. Park, M.-J. Ahn
Journal: Journal of Thoracic Oncology (2023)
P1.21-14 LIPI-based Score Predicting OS Benefit for the Addition of Chemotherapy to Pembrolizumab in aNSCLC with PD-L1 TPS≥50%
Authors: A. Raphael, A. Kamm Feldman, W. Kian, K. Hod, I. Lazarev, W. Shalata, H. Nechushtan, M. Moskovitz, E. Dudnik
Journal: Journal of Thoracic Oncology (2023)
P2.06-10 Disease Progression on PROs in Patients With aNSCLC With PD-L1 ≥50% Receiving Cemiplimab vs Chemotherapy: EMPOWER-Lung 1
Authors: M. Gümüs, S. Kilickap, A. Sezer, I. Bondarenko, M. Özgüroğlu, M. Gogishvili, X. He, G. Gullo, P. Rietschel, R.G. Quek
Journal: Journal of Thoracic Oncology (2023)
P1.03-01 Dynamic Transcriptomic Characterization Changes of Early Stage Lung Adenocarcinoma as per the Incrassation of Consolidation Tumor Ratio
Authors: Z-b. Qiu, J. Li, H.-J. Li, M.-M. Wang, Y.-L. Wu, X. Zhang, W.-Z. Zhong
Journal: Journal of Thoracic Oncology (2023)
P1.24-02 Mortality Benefit of a 4-Protein Blood-Based Biomarker Panel for Lung Cancer
Authors: E. Ostrin, E. Irajizad, T. Marsh, J. Vykoukal, J.P. Long, K.-A. Do, Z. Feng, J.F. Fahrmann, S. Hanash
Journal: Journal of Thoracic Oncology (2023)
P1.23-07 Clinical Impact of Clonal Hematopoiesis in Patients with Advanced Non-small Cell Lung Cancer: Results of the CHIC Study
Authors: M. Tagliamento, C. Marzac, M. Aldea, D. Vasseur, A. Bayle, A. Gazzah, M. Ngocamus, C. Nicotra, A. Levy, C. Baldini, F. Blanc-Durand, E. Rouleau, A. Italiano, L. Lacroix, L. Friboulet, D. Planchard, F. Barlesi, Y. Loriot, J.-B. Micol, B. Besse
Journal: Journal of Thoracic Oncology (2023)
EP16.01-05 Creation of Mental Health Support Materials for People with Lung Cancer and Healthcare Providers (HCPs)
Authors: S. Shilo, D. Montague, M. Brooke, A.-M. Baird, S. Vallone, C. Schmitt-Plank, A. O'Meara, Z. Sithole, E. De Jong, A. Nunez, E. Prazakova, L. Potenciano
Journal: Journal of Thoracic Oncology (2023)
P1.21-20 Tertiary Lymphoid Structures Assessed by an AI-powered Analysis of H&amp;E Images is Correlated with Favorable Outcomes of Immunotherapy in NSCLC
Authors: L. Kim, H.S. Kim, M. Nam, J. Lee, L.I.-Y. Chung, M.j. Aguilera Chuchuca, S. Shin, C. Ahn, M. Seo, T. Lee, S. Song, B. Alexiev, C.-Y. Ock, Y.K. Chae
Journal: Journal of Thoracic Oncology (2023)
P1.09-01 Anti-Cancer Immune Activation Post Bronchoscopic Thermal Ablation in Non-Small Cell Lung Cancer
Authors: K. Rangamuwa, M. Christie, T. Leong, C. Aloe, K. Yokote, D. Batey, M.-L. Asselin-Labat, P. Antippa, L. Irving, S. Bozinovski, D. Steinfort
Journal: Journal of Thoracic Oncology (2023)
P2.18-04 Real-world Study on Efficacy of First-Line Nivolumab + Ipilimumab in Unresectable Malignant Pleural Mesothelioma (ImmunoMeso)
Authors: E.D. Aguirre, D.H. Enrico, N.S. Tissera, F. Tsou, C. Pupareli, D. Peralta, F. Waisberg, A. Rodríguez, D. Kaen, G. Recondo, M. Ramos, V. Bluthgen, N. Castagneris, A. Perfetti, P. Levit, M. Chacón, L. Corrales, O. Arrieta, A.F. Cardona, C. Martín
Journal: Journal of Thoracic Oncology (2023)
MA07.09 Adapted Physical Activity (AMAti) Program for Lung Cancer Patients Realized by WALCE (Women Against Lung Cancer in Europe)
Authors: S. Vallone, S. Carnio, D. Mirandola, S. Pilotto, A. Avancini, E. Garbo, G. Bernardi, C. Destro, S. Torri, A. Collevecchio, R. Riccardi, S. Mariotti, V. Scotti, E. Olmetto, D. Galetta, A. Catino, V. Longo, D. Bafunno, M.V. Pacchiana Parravicini, S. Novello
Journal: Journal of Thoracic Oncology (2023)
P1.24-05 The Association of Acinar Pattern with Clinicopathological, Molecular Features, and Prognosis in Lung Adenocarcinoma Patients
Authors: H. Abolfathi, D. Boudreau, V. Saavedra Armero, N. Gaudreault, M. Orain, P.O. Fiset, P. Desmeules, A. Gagné, F. Lamaze, Y. Bossé, P. Joubert
Journal: Journal of Thoracic Oncology (2023)
P2.09-28 Effect of TP53 Variants in HER2-mutated Non-Small Cell Lung Cancer (NSCLC)
Authors: J. Feng, K. Hueniken, Z.J. Fan, L. Corke, N.B. Leighl, G. Liu, P.A. Bradbury, A. Sacher, L. Eng, T. Stockley, M.S. Tsao, F. Shepherd
Journal: Journal of Thoracic Oncology (2023)
P1.23-06 Liquid Biopsy Predicts Differential Benefit from First Line Pembrolizumab in Advanced Non-small Cell Lung Cancer
Authors: L. Bonanno, E. Zulato, P. Del Bianco, A. Boscolo Bragadin, I. Attili, A. Pavan, G. Nardo, A. Dal Maso, S. Frega, A. Ferro, G. Pasello, M. Fassan, F. Calabrese, V. Guarneri, S. Indraccolo
Journal: Journal of Thoracic Oncology (2023)
MA05.05 Patient Reported Experience as a Baseline for 4R Care Sequence Implementation at 8 Cancer Centers
Authors: K. Prescott, C.B. Weldon, N. Mohindra, L.E. Feldman, M.M. Pasquinelli, R.H. Nguyen, F. Weinberg, C. Chan, S. Houseknecht, J. Feliciano, R. Sacks, J.W. Carlisle, W. Waugh, J. Martin, J. Woodyard, P. Khosla, S. Khan, A. Ravelo, T. Lycan, N. Martin, L. Boehmer, J.R. Trosman
Journal: Journal of Thoracic Oncology (2023)
P1.26-06 Harmonized Maximum Standardized Uptake Value as an Indicator for Sublobar Resection: A Multicenter Retrospective Study
Authors: M. Adachi, Y. Yoshida, M. Yotsukura, K. Nakagawa, A. Hamada, K. Kitajima, K. Suda, T. Koga, J. Soh, H. Kaida, K. Ito, T. Sekine, H. Daisaki, M. Hashimoto, K. Takegahara, T. Kabasawa, T. Yamasaki, S. Hirota, J. Usuda, None k. Ishii, S-i. Watanabe, T. Mitsudomi
Journal: Journal of Thoracic Oncology (2023)
P1.22-18 Immediate Biomarkers Profiling of Actionable NSCLC Panel from a Digitized H&amp;E Biopsy Image
Authors: N. Paz-Yaacov, E. Ofek, R. Haj, R. Yacobi, C. Mayer, C. Avivi, J. Zalach, I. Gazy, N. Peled, J. Bar, D. Hershkovitz, I. Barshack
Journal: Journal of Thoracic Oncology (2023)
MA17.05 Real World Outcomes of Immunotherapy (IO) for Pleural MESOthelioma in Australia - RIOMeso
Authors: N. McNamee, C. Harvey, L. Gray, T. Khoo, L. Lingam, B. Zhang, T. Clay, S. Arulananda, M. Itchins, N. Pavlakis, S. Kao, S. Bowyer, V. Chin, L. Warburton, I. da Silva, T. John, B. Solomon, M. Alexander, A. Nagrial
Journal: Journal of Thoracic Oncology (2023)
P2.09-13 QT-interval Prolongation and Torsades de Pointes With EGFR TKIs in NSCLC: Targeted Literature Review
Authors: B. Khokhar, B. Chiang, K. Iglay, K. Reynolds, N. Rodriguez-Ormaza, W. Spalding, E. Freedland
Journal: Journal of Thoracic Oncology (2023)
P1.18-06 Barriers to Completing Low Dose CT Scan for Lung Cancer Screening
Authors: L.-Y. Wong, S. Choudhary, M. Lin, I. Elliott, B.A. Guenthart, D.Z. Liou, L. Backhus, M.F. Berry, J.B. Shrager, N. Lui
Journal: Journal of Thoracic Oncology (2023)
MA16.09 Evaluation of the Diagnostic Performance of AI Accompanied by CT Images in the Differentiation of Malignant or Benign MLN in NSCLC
Authors: Y. Kahya, K. Orhan, Ç. Uzun, H. Nalbant Özakıncı, D. Karasoy, A.U. Yücemen, A. Kayı Cangır
Journal: Journal of Thoracic Oncology (2023)
P2.11-02 Tepotinib in Asian Patients with MET exon 14 Skipping Non-small Cell Lung Cancer (NSCLC) in Long-term Follow-up From VISION
Authors: M.-J. Ahn, T. Kato, J.C.-H. Yang, H. Sakai, M. Morise, Y.-M. Chen, J.-Y. Han, J.-J. Yang, J. Zhao, T.-C. Hsia, K. Berghoff, R. Bruns, H. Vioix, S. Lang, A. Johne, X. Le, P.K. Paik
Journal: Journal of Thoracic Oncology (2023)
P1.17-04 Lung-Cancer Screening: Is It Worth Investing? Evidence from a Population-Based Markov Study in Italy
Authors: L. Fiestas-Navarrete, S. Ghislandi, P. Muriana, P. Novellis, E. Dieci, G. Favaro, G. Mangiameli, E. Lanza, G. Veronesi
Journal: Journal of Thoracic Oncology (2023)
MA01.03 Thromboprophylaxis for Lung Cancer Patients: Combined Results from GMaT and ACT4CAT Studies
Authors: N.G. Tsoukalas, A. Christopoulou, E. Timotheadou, A. Koumarianou, A. Ardavanis, I. Athanasiadis, S. Demiri, A. Bokas, G. Samelis, S. Peroukidis, G. Papatsimpas, C. Andreadis, A. Nikolakopoulos, A. Psyrri, N. Kapodistrias, P. Papakostas, G. Aravantinos, A. Athanasiadis, P. Papakotoulas, I. Boukovinas
Journal: Journal of Thoracic Oncology (2023)
OA08.05 Implementation and Evaluation of a Geriatric Oncology Model of Care for Older Patients with Lung Cancer
Authors: S. Vinod, A. Khoo, M. Berry, K. Bell, E. Ahmed, C. Gollon, A. Pal, S.K. Seto, T. Tran, V. Bray
Journal: Journal of Thoracic Oncology (2023)
P2.02-02 Pneumonitis Rates Before Versus After Adoption of Immunotherapy Consolidation for Locally Advanced Non-Small Cell Lung Cancer
Authors: N. Yegya-Raman, C. Friedes, M. Iocolano, S.H. Lee, W. Su, L. Duan, B. Li, A. Doucette, W.P. Levin, K.A. Cengel, D. DiBardino, R. Cohen, L. Sun, C. Aggarwal, K. Teo, S. O'Reilly, Y. Xiao, J.D. Bradley, C.J. Langer, S.J. Feigenberg
Journal: Journal of Thoracic Oncology (2023)
MA05.06 Lung Cancer Patients' Preferred Method of Contact with Their Treatment Team in Different Situations: Insights From a Global Experience Survey
Authors: S. Pook, J. Fenemore, C. Ference, J. Fox, B. Gaspar, M. Hennink, J. Mayans, A. McNamara, L. Pretorius, M. Rigney, M. Daniels, S. Pook
Journal: Journal of Thoracic Oncology (2023)
MA06.08 Real-World Landscape Analysis of Activating ERBB2/ERBB3 Alterations in 107,561 Tissue and Plasma Samples from Patients with NSCLC
Authors: D. Liu, J. Jee, R.B. Keller, A.B. Schrock, A. Drilon, G.R. Oxnard, B.T. Li
Journal: Journal of Thoracic Oncology (2023)
MA06.03 KontRASt-01: Preliminary Safety and Efficacy of JDQ443 + TNO155 in Patients with Advanced, KRAS G12C-Mutated Solid Tumors
Authors: M.V. Negrao, P.A. Cassier, B. Solomon, M. Schuler, K. Rohrberg, S. Cresta, C. Dooms, D.S.W. Tan, H.H-f. Loong, A. Amatu, K. Krueger Assmann, L. Fairchild, L. Sansregret, L. Fan, A.F. Farago, B.C. Cho
Journal: Journal of Thoracic Oncology (2023)
MA13.11 Lazertinib for Patients with NSCLC Harboring Uncommon EGFR Mutations: A Single-Arm, Phase II Multi-Center Trial
Authors: S. Park, H.K. Ahn, S. Lee, Y.J. Min, H.A. Jung, J.-M. Sun, S-H. Lee, J.S. Ahn, M.-J. Ahn, J.B. Lee, S.M. Kim, H.R. Kim, B.C. Cho, M.H. Hong
Journal: Journal of Thoracic Oncology (2023)